Literature DB >> 30108966

Schizophrenia: synthetic strategies and recent advances in drug design.

Maria Azmanova1, Anaïs Pitto-Barry1, Nicolas P E Barry1.   

Abstract

Schizophrenia is a complex and unpredictable mental disorder which affects several domains of cognition and behaviour. It is a heterogeneous illness characterised by positive, negative, and cognitive symptoms, often accompanied by signs of depression. In this tutorial review, we discuss recent progress in understanding the target sites and mechanisms of action of second-generation antipsychotic drugs. Progress in identifying and defining target sites has been accelerated recently by advances in neuroscience, and newly developed agents that regulate signalling by the main excitatory neurotransmitters in the brain are surveyed. Examples of novel molecules for the treatment of schizophrenia in preclinical and clinical development and their industrial sponsors are highlighted.

Entities:  

Year:  2018        PMID: 30108966      PMCID: PMC6072500          DOI: 10.1039/c7md00448f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  136 in total

1.  A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

Authors:  Amit Taneja; An Vermeulen; Dymphy R H Huntjens; Meindert Danhof; Elizabeth C M De Lange; Johannes H Proost
Journal:  Eur J Pharmacol       Date:  2016-07-06       Impact factor: 4.432

2.  In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.

Authors:  P W Chiu; Simon S Y Lui; Karen S Y Hung; Raymond C K Chan; Queenie Chan; P C Sham; Eric F C Cheung; Henry K F Mak
Journal:  Schizophr Res       Date:  2017-07-25       Impact factor: 4.939

3.  Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.

Authors:  Simon E Ward; Paul Beswick; Novella Calcinaghi; Lee A Dawson; Jane Gartlon; Francesca Graziani; Declan N C Jones; Laurent Lacroix; M H Selina Mok; Beatrice Oliosi; Joanne Pardoe; Kathryn Starr; Marie L Woolley; Mark H Harries
Journal:  Br J Pharmacol       Date:  2017-01-31       Impact factor: 8.739

4.  Antipsychotic haloperidol binding to the human dopamine D3 receptor: beyond docking through QM/MM refinement toward the design of improved schizophrenia medicines.

Authors:  Geancarlo Zanatta; Gustavo Nunes; Eveline M Bezerra; Roner F da Costa; Alice Martins; Ewerton W S Caetano; Valder N Freire; Carmem Gottfried
Journal:  ACS Chem Neurosci       Date:  2014-09-18       Impact factor: 4.418

5.  Don't fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert.

Authors:  Jonathan Michael Pell; Dora Cheung; Michael A Jones; Ethan Cumbler
Journal:  J Am Med Inform Assoc       Date:  2014-06-13       Impact factor: 4.497

6.  Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.

Authors:  Kathryn M Avent; J J DeVoss; Elizabeth M J Gillam
Journal:  Chem Res Toxicol       Date:  2006-07       Impact factor: 3.739

7.  Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.

Authors:  Y von Coburg; T Kottke; L Weizel; X Ligneau; H Stark
Journal:  Bioorg Med Chem Lett       Date:  2008-09-07       Impact factor: 2.823

8.  7-Chloro-5-(furan-3-yl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-Dioxide as Positive Allosteric Modulator of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor. The End of the Unsaturated-Inactive Paradigm?

Authors:  Cinzia Citti; Umberto M Battisti; Giuseppe Cannazza; Krzysztof Jozwiak; Natalia Stasiak; Giulia Puja; Federica Ravazzini; Giuseppe Ciccarella; Daniela Braghiroli; Carlo Parenti; Luigino Troisi; Michele Zoli
Journal:  ACS Chem Neurosci       Date:  2015-12-02       Impact factor: 4.418

Review 9.  Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.

Authors:  Clive Elliott Adams; John Rathbone; Ben Thornley; Mike Clarke; Jo Borrill; Kristian Wahlbeck; A George Awad
Journal:  BMC Med       Date:  2005-10-17       Impact factor: 8.775

Review 10.  Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Authors:  James Maksymetz; Sean P Moran; P Jeffrey Conn
Journal:  Mol Brain       Date:  2017-04-26       Impact factor: 4.041

View more
  3 in total

1.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

2.  An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.

Authors:  Jacob D Porter; Oscar Vivas; C David Weaver; Abdulmohsen Alsafran; Elliot DiMilo; Leggy A Arnold; Eamonn J Dickson; Chris Dockendorff
Journal:  Bioorg Med Chem Lett       Date:  2019-09-14       Impact factor: 2.823

Review 3.  Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics.

Authors:  Andrea de Bartolomeis; Licia Vellucci; Mark C Austin; Giuseppe De Simone; Annarita Barone
Journal:  Biomolecules       Date:  2022-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.